BIO’s Industry Analysis Team presents Emerging Therapeutic Company trends across five core areas of investment and deal-making: venture capital, initial public offerings (IPOs), follow-on public offerings, licensing, and acquisitions. Emerging Therapeutic Companies, which represent 95% of drug development companies, are those in R&D-stage drug development or at market-stage but with less than $1 billion in sales.
View other BIO Industry Analysis Team reports.
